COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I FLVFLV REGNR2 LY-CoVLY RemdesivirRMD
Ivermectin study #21 of 63
10/26 Late treatment study
Hashim et al., medRxiv, doi:10.1101/2020.10.26.20219345 (Preprint)
Controlled randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad, Iraq
Source   PDF   Share   Tweet
RCT 70 ivermectin-doxycycline patients and 70 control patients showing reduced time to recovery and reduced mortality with treatment.
The earlier ivermectin+doxycycline was administered, the higher rate of successful therapy.

Hashim et al., 10/26/2020, Single Blind Randomized Controlled Trial, Iraq, Middle East, preprint, 6 authors, dosage 200μg/kg days 1-2, some patients received a third dose on day 8.
risk of death, 66.7% lower, RR 0.33, p = 0.27, treatment 2 of 70 (2.9%), control 6 of 70 (8.6%), all patients.
risk of death, 91.7% lower, RR 0.08, p = 0.03, treatment 0 of 59 (0.0%), control 6 of 70 (8.6%), excluding critical patients.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 63 studies    Meta analysis
Please send us corrections, updates, or comments.
Submit